Prostaglandin E2 activates the mTORC1 pathway through an EP 4 /cAMP/ PKA- and EP 1 /Ca 2 -mediated mechanism in the human pancreatic carcinoma

[1]  N. Demartines,et al.  PGE2-induced colon cancer growth is mediated by mTORC1. , 2014, Biochemical and biophysical research communications.

[2]  R. Pepperkok,et al.  Plasma membrane translocation of REDD1 governed by GPCRs contributes to mTORC1 activation , 2014, Journal of Cell Science.

[3]  Huamin Wang,et al.  Combined Targeting of STAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer , 2014, Clinical Cancer Research.

[4]  C. Roland,et al.  A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. , 2013, Gastroenterology.

[5]  M. Smyth,et al.  A balance of interleukin-12 and -23 in cancer. , 2013, Trends in immunology.

[6]  M. McArthur,et al.  Dietary Energy Balance Modulation of Kras- and Ink4a/Arf+/−-Driven Pancreatic Cancer: The Role of Insulin-like Growth Factor-I , 2013, Cancer Prevention Research.

[7]  Gang Li,et al.  High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the Conditional KrasG12D Mouse Model , 2013, Cancer Prevention Research.

[8]  Yanping Zhang,et al.  Increased Th17 Cells in the Tumor Microenvironment Is Mediated by IL-23 via Tumor-Secreted Prostaglandin E2 , 2013, The Journal of Immunology.

[9]  C. Hudis,et al.  Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer , 2013, Cancer Prevention Research.

[10]  D. Rosenberg,et al.  Multifaceted roles of PGE2 in inflammation and cancer , 2013, Seminars in Immunopathology.

[11]  C. Hudis,et al.  Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. , 2012, Cancer discovery.

[12]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[13]  J. Olefsky,et al.  The cellular and signaling networks linking the immune system and metabolism in disease , 2012, Nature Medicine.

[14]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[15]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[16]  P. Bracci.  Obesity and pancreatic cancer: Overview of epidemiologic evidence and biologic mechanisms , 2012, Molecular carcinogenesis.

[17]  B. Spiegelman,et al.  Molecular mechanisms of cancer development in obesity , 2011, Nature Reviews Cancer.

[18]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[19]  B. Hennessy,et al.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.

[20]  J. Dumont,et al.  cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. , 2010, Molecular endocrinology.

[21]  E. Rozengurt,et al.  Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer , 2010, Clinical Cancer Research.

[22]  I. Kettelhut,et al.  Involvement of cAMP/Epac/PI3K-dependent pathway in the antiproteolytic effect of epinephrine on rat skeletal muscle , 2010, Molecular and Cellular Endocrinology.

[23]  J. Melo,et al.  Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway , 2010, Oncogene.

[24]  G. Eibl,et al.  Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. , 2009, Cancer research.

[25]  L. Marnett.  The COXIB experience: a look in the rearview mirror. , 2009, Annual review of pharmacology and toxicology.

[26]  Heather R. Roberts,et al.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. , 2009, Carcinogenesis.

[27]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[28]  F. Natt,et al.  Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. , 2008, Cell metabolism.

[29]  H. Reber,et al.  Opposing Effects of n-6 and n-3 Polyunsaturated Fatty Acids on Pancreatic Cancer Growth , 2008, Pancreas.

[30]  H. Reber,et al.  Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. , 2007, Cancer research.

[31]  S. H. Young,et al.  Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. , 2007, Endocrinology.

[32]  J. Blenis,et al.  RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation* , 2007, Journal of Biological Chemistry.

[33]  S. Narumiya,et al.  Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.

[34]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[35]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[36]  D. Albanes,et al.  Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. , 2005, JAMA.

[37]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[38]  J. Frystyk.  Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[39]  M. Hull,et al.  Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? , 2004, Molecular cancer therapeutics.

[40]  J. Morrow,et al.  Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation* , 2004, Journal of Biological Chemistry.

[41]  Jung Hun Song,et al.  Regulation of the Phosphatidylinositol 3-Kinase, Akt/Protein Kinase B, FRAP/Mammalian Target of Rapamycin, and Ribosomal S6 Kinase 1 Signaling Pathways by Thyroid-stimulating Hormone (TSH) and Stimulating type TSH Receptor Antibodies in the Thyroid Gland* , 2003, Journal of Biological Chemistry.

[42]  M. Imbert-Teboul,et al.  Protein Kinase A-independent Activation of ERK and H,K-ATPase by cAMP in Native Kidney Cells , 2002, The Journal of Biological Chemistry.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  T. Sugimura,et al.  Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. , 2001, Carcinogenesis.

[45]  S. Narumiya,et al.  Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. , 1999, Cancer research.

[46]  E. Wynder,et al.  Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. , 1999, Cancer research.

[47]  A. Wittinghofer,et al.  Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP , 1998, Nature.

[48]  Bandaru S. Reddy,et al.  Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. , 1997, Cancer research.

[49]  S. Ferrari,et al.  Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. , 1993, The Journal of biological chemistry.

[50]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[51]  D. Kusewitt,et al.  Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. , 2006, The Journal of investigative dermatology.

[52]  S. Narumiya,et al.  Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.